Kevin Denny, DABT (1994–2024), is Executive Director of Toxicology at WuXi AppTec. He is a board-certified nonclinical toxicologist with more than 40 years in pharmaceutical drug development. A recognized expert in Developmental & Reproductive Toxicology (DART), regulatory strategy, and quality, he designs IND-enabling programs that balance rigor and speed. Kevin has led cross-functional teams in pharma, biotech, and CRO settings; directed pharmacology, ADME, and GLP toxicology studies; and guided multiple programs to successful IND, NDA, and BLA submissions. His therapeutic focus spans CNS, neurology, neurodegeneration, and pain. He has established and managed GLP laboratories in the U.S. and France, overseen extensive study outsourcing, and built high-trust collaborations with CROs and investigators. Kevin’s specialty is translating complex science into streamlined, regulator-ready packages that keep development on track.